biotech announces - Robuta Search

https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/134-2026-news/1035-pds-biotech-announces-publication-of-positive-pds01adc-inter2026-04-15-055033 PDS Biotech - PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial... pds biotech announces publication positive interim phase https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/131-2024-news/945-iotechnnouncespdatedesultsfrom002h20240916 PDS Biotech - PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial... PDS Biotech is committed to developing novel and effective therapies based on the Versamune® platform to save and improve the lives of cancer patients... pds biotech announces updated results versatile phase https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/131-2024-news/952-iotechnnounces36onthverallurvivalateof8420241002 PDS Biotech - PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced... PDS Biotech is committed to developing novel and effective therapies based on the Versamune® platform to save and improve the lives of cancer patients... pds biotech announces month overall survival rate https://www.openzone.it/en/act/news/ZBIOTECH_IPX203 Zambon Biotech announces first patient dosed in Phase 3b ADIP clinical study of IPX203 in... Zambon Biotech announces a first milestone in Phase 3b ADIP clinical study of IPX203 for Parkinson’s disease biotech announces first patient clinical study zambon phase https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/125-2023-news/885-iotechnnouncespdatedurvivalatafromedh20231109 PDS Biotech - PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of... PDS Biotech is committed to developing novel and effective therapies based on the Versamune® platform to save and improve the lives of cancer patients... pds biotech announces clinical trial updated survival data https://biotechdispatch.com.au/news/emyria-announces-an-expansion-of-empax-clinics-into-new-south-wales Emyria announces an expansion of Empax clinics into New South Wales - Biotech Emyria has reached an agreement with Matilda Healthcare to open an Empax clinic at Matilda Nepean Private Hospital in Kingswood, expanding the company's... new south wales announces expansion clinics biotech https://biotechdispatch.com.au/news/arovella-announces-board-overhauled-and-ceo-resignation Arovella announces board overhaul and CEO resignation - Biotech Arovella Therapeutics has updated investors, advising that a requisitioning shareholder had served a notice under the Corporations Act seeking the removal of... announces board overhaul ceo resignation biotech